DMRTC2: A Potential Drug Target for Cancer (G63946)

Target Name: DMRTC2

NCBI ID: G63946

DMRTC2

Other Name(s): Doublesex- and mab-3-related transcription factor C2 | DMRT like family C2 | DMRTD_HUMAN | doublesex- and mab-3-related transcription factor C2 | Doublesex and Mab-3 related transcription factor C2

DMRTC2: A Potential Drug Target for Cancer

Double-stranded RNA transcribing factors (DNRTF) are a family of proteins that play a crucial role in gene expression and are involved in the regulation of RNA polymerase II (RNA-pol) initiation. DNRTFs are composed of several subunits, including C2, which is a key subunit involved in the regulation of RNA-pol initiation. C2 is a 21-kDa protein that contains a N-terminal alpha-helix, a central 尾-sheet, and a C-terminal T-loop. The C2 subunit is Highly conserved across different species, and its function is conserved from mouse to human.

DMRTC2, a protein related to C2, is a key regulator of RNA-pol initiation and has been identified as a potential drug target. DMRTC2 functions as a negative regulator of RNA-pol by binding to the alpha-2 portion of the core RNA- pol subunit and preventing its phosphorylation. This interaction between DMRTC2 and RNA-pol has important implications for the regulation of gene expression, as RNA-pol is a key enzyme involved in the production of RNA from DNA templates.

Expression and function of DMRTC2

DMRTC2 is a protein that is expressed in various tissues and cells, including brain, heart, and muscle. It is primarily localized to the cytoplasm and is associated with the endoplasmic reticulum (ER). DMRTC2 is a scaffold protein that can interact with various cellular structures, including the ER and the nuclear envelope. It is involved in the regulation of protein stability and in the assembly of the endoplasmic reticulum.

DMRTC2 functions as a negative regulator of RNA-pol by binding to the alpha-2 portion of the core RNA-pol subunit and preventing its phosphorylation. This interaction between DMRTC2 and RNA-pol has important implications for the regulation of gene expression. The alpha -2 region of RNA-pol is critical for its function, as it contains the site where the protein interacts with the template RNA. The binding of DMRTC2 to the alpha-2 region blocks the interaction between RNA-pol and the template RNA, preventing the phosphorylation of the alpha-2 region and subsequent initiation of RNA-pol.

DMRTC2 has been shown to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation. For example, studies have shown that DMRTC2 is involved in the regulation of cell cycle progression, and that it promotes the G1 /S transition and the G2/M transition. It has also been shown to be involved in the regulation of apoptosis, as it has been shown to promote the formation of apoptotic cells in response to various stimuli.

DMRTC2 has also been shown to play a role in the regulation of gene expression. It has been shown to interact with various transcription factors, including RNA-pol, and to regulate their activity. For example, studies have shown that DMRTC2 can interact with the RNA-pol subunit and prevent its phosphorylation, thereby inhibiting the initiation of RNA-pol. This interaction between DMRTC2 and RNA-pol has important implications for the regulation of gene expression, as RNA-pol is a key enzyme involved in the production of RNA from DNA templates.

Drug targeting DMRTC2

DMRTC2 is a potential drug target due to its involvement in the regulation of gene expression and its function as a negative regulator of RNA-pol. Drugs that target DMRTC2 have been shown to have various therapeutic effects, including the inhibition of cancer growth and the regulation of cell cycle progression.

One of the most promising drugs that targets DMRTC2 is currently in clinical trials for the treatment of various cancers, including breast, ovarian, and colorectal cancers. This drug, called DMRTC2 inhibitor, is an oral small molecule that targets DMRTC2 and inhibits its function as a negative regulator of RNA-pol. Studies have shown that this drug has been effective in inhibiting the growth of various cancer cell lines and has the potential to be a useful therapeutic for cancer treatment.

Conclusion

DMRTC2 is a protein that is involved in the regulation of gene expression and has been shown to play a

Protein Name: DMRT Like Family C2

Functions: May be involved in sexual development

The "DMRTC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DMRTC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets